Company Performance Metrics
As of May 28, 2009, Avalon Pharmaceuticals, Inc. was acquired by Clinical Data, Inc. Avalon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics using its proprietary AvalonRx technology in the United States. The company’s lead product candidate, AVN944, an inosine
monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Avalon Pharmaceuticals has drug discovery, development, and commercialization agreement with Merck & Co., Inc. to identify and develop inhibitors against a selected target in the area of oncology; a collaboration and license agreement with MedImmune, Inc. for the discovery of small molecule therapeutic compounds in the area of inflammatory disease; a collaboration agreement with ChemDiv, Inc. for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex, Inc. to jointly research, develop, and commercialize human antibodies against the company’s cancer targets; and an agreement with Novartis Institutes for Biomedical Research, Inc. for the discovery of small molecule therapeutic compounds. The company was incorporated in 1999 and is headquartered in Germantown, Maryland.
